Skip to main content

Edgewise Therapeutics, Inc 8-K, filed Nov 4, 2026

Edgewise Therapeutics, Inc. (EWTX)

8-K 2026-11-04 For: 2026-11-04
View Original
Added on November 04, 2026

About this 8-K

Edgewise Therapeutics, Inc filed this 8-K on November 4, 2026.

Edgewise Therapeutics, Inc. reported $1,166.2 million in third-quarter net income, including a $1.348 billion gain from the sevasemten sale, and expects to initiate the EDG-7500 Phase 3 trial by year-end 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits